Xiidra (lifitegrast)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Lifitegrast, an integrin lymphocyte function-associated antigen-1 (LFA-1) inhibitor, is an anti-inflammatory agent.
Lifitegrast, an integrin lymphocyte function-associated antigen-1 (LFA-1) antagonist, is an anti-inflammatory agent.
The interaction between LFA-1, a cell surface protein found on leukocytes, and its cognate ligand intercellular adhesion molecule-1 (ICAM-1) contributes to T-cell activation and migration to target tissues and secretion of inflammatory cytokines. The binding of lifitegrast to LFA-1 blocks the interaction between LFA-1 and ICAM-1, thereby inhibiting T-cell adhesion to ICAM-1 and secretion of cytokines. Although the exact mechanism of action of lifitegrast in dry eye disease is not known, ICAM-1 may be overexpressed in corneal and conjunctival tissues in patients with dry eye disease and T-cell-mediated inflammation may play a role in the disease.
Lifitegrast is rapidly absorbed into ocular tissues following topical application. Peak tear concentrations occur 0.3 hours after twice-daily administration. Topical administration of lifitegrast ophthalmic solution does not produce clinically important systemic exposure of lifitegrast or systemic inhibition of lymphocyte function.
Following administration of lifitegrast 5% ophthalmic solution to the eye (1 drop twice daily) for 180 and/or 360 days, 19% of patients had lifitegrast trough concentrations above the lower limit of quantitation (0.5 ng/mL). The drug is cleared from plasma in 1-4 hours after topical application to the eye.
USES: This medication is used to treat dry eye disease.
Generic name: lifitegrast
Pronunciation: (LIF-i-TEG-rast)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Xiidra
Indications
The following indications are listed for Xiidra:
- Tear Film Insufficiency
Also known as: Dry Eyes Syndrome.
Dosing
The recommended dosage of lifitegrast in the management of dry eye disease in adults is 1 drop of a 5% ophthalmic solution in each eye twice daily, administered approximately 12 hours apart.
Lifitegrast is applied topically to the eye as an ophthalmic solution. The ophthalmic solution is for topical ophthalmic use only. Care should be taken to avoid eye injury or contamination of the solution container. The tip of the single-use container should not touch the eye or any other surface.
Contact lenses should be removed prior to administration of lifitegrast ophthalmic solution and may be reinserted 15 minutes after administration.
Single-use containers of lifitegrast ophthalmic solution should not be removed from the foil pouch until ready to use. After removing a single-use container from the foil pouch, the remaining containers should be placed back in the pouch and the edge should be folded to close the pouch.
There is a sufficient amount of lifitegrast ophthalmic solution in each single-use container for administration of 1 dose into each eye. The preservative-free solution is for single use only and any unused portion should be discarded immediately after administration.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
No formal drug interaction studies involving lifitegrast ophthalmic solution have been performed.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
Manufacturer states none known.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
The most common adverse effects of lifitegrast ophthalmic solution (reported in 5-25% of patients) are instillation site irritation, dysgeusia, and reduced visual acuity. Other adverse effects (occurring in 1-5% of patients) include ocular effects such as blurred vision, conjunctival hyperemia, irritation, increased lacrimation, discharge, discomfort, and pruritus as well as nonocular effects such as headache and sinusitis.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
Safety and efficacy of lifitegrast ophthalmic solution have not been established in pediatric patients younger than 17 years of age.
There are no data available regarding the use of lifitegrast ophthalmic solution in pregnant women. In pregnant rats, IV administration of lifitegrast did not result in teratogenic effects at relevant systemic exposures. In pregnant rabbits, IV administration of lifitegrast 3 mg/kg per day (400-fold human plasma exposures at the recommended ophthalmic dosage) increased incidence of omphalocele.
It is not known whether lifitegrast is distributed into human milk following topical application to the eye. There are no data available regarding lifitegrast effects on the breast-fed infant or milk production. Although systemic exposure to lifitegrast after ophthalmic administration is low, the developmental and health benefits of breast-feeding should be considered along with the mother's clinical need for the drug and any potential adverse effects on the infant from lifitegrast.
No overall differences in safety or efficacy have been observed between geriatric patients and younger adults.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.